The Advancing Gene Editing Therapy for Cardiovascular Disease Heart House Roundtable convenes a diverse, multidisciplinary group of experts to explore the promise and challenges of gene editing in treating ATTR and hyperlipidemia. With technologies like CRISPR entering clinical trials and demonstrating early evidence of durable, one-time therapeutic effects, the landscape of cardiovascular care is poised for a paradigm shift. Gene editing holds promise for silencing or correcting disease-driving genes—such as TTR in ATTR and PCSK9 in hyperlipidemia—offering alternatives to lifelong medication and mitigating progressive disease.